Jeuveau is the newest widely marketed botulinum toxin and Juvederm is the biggest filler brand family, and they treat completely different things. Jeuveau relaxes one muscle group. Juvederm adds volume to a specific area. Neither can do the other's job.
Jeuveau's approval is unusually narrow, and that is the most useful fact on this page. Jeuveau (prabotulinumtoxinA-xvfs, from Evolus) was approved by the FDA on 1 February 2019 for glabellar lines only - the frown lines between the brows. Its label dose is 20 Units, given as 4 Units at each of five sites. Those are Jeuveau Units: the label states plainly that "Potency Units of JEUVEAU are not interchangeable with other preparations of botulinum toxin products."
Juvederm is a family, not a product. Each gel has its own FDA approval, its own approved area and its own trial numbers: Voluma XC for cheeks, chin and temples; Ultra XC for facial wrinkles and folds and for lips; Volbella XC for lips, perioral lines and under-eye hollows; Vollure XC for facial wrinkles and folds; Volux XC for jawline definition; Skinvive for cheek smoothness and neck lines. A figure from one does not apply to another.
No trial has compared Jeuveau against any filler, and none could usefully be run. Jeuveau's own comparative trial was against Botox Cosmetic, and it was a non-inferiority study - a design that can show a product is not meaningfully worse than the comparator, and cannot show it is better.
Class III devices approved through the FDA's premarket approval route, which required evidence for one named area at a time.
It blocks the release of the chemical signal that makes a muscle contract, so the muscle relaxes. Nothing is added.
Voluma XC: cheeks (2013), chin (2020), temples (2023). Ultra XC: facial wrinkles and folds, plus lips (2015). Volbella XC: lips and perioral lines (2016), under-eye hollows (2021). Volux XC: jawline definition (2022). Skinvive: cheek smoothness (2023) and neck lines (2026).
Jeuveau holds no US approval for forehead lines, crow's feet or any other cosmetic area. Daxxify and Letybo are also glabellar-only; Botox Cosmetic and Xeomin hold wider cosmetic approvals.
Never convert this figure into another brand's units. Laboratory work comparing the two molecules found onabotulinumtoxinA showed 1.33 to 1.51 times higher activity than prabotulinumtoxinA across three different assays - that study was aligned with Allergan, the maker of the competing product.
The Juvederm Volbella XC lip trial used Restylane-L as the control, and the Restylane Contour cheek trial used Juvederm Voluma XC as the control. The Contour trial was a non-inferiority design; the Volbella trial was an active-controlled trial that the approval documents do not present as a superiority result. Neither produced a winner.
Subjects were randomized 5:5:1 to 20 Units of Jeuveau, 20 Units of Botox Cosmetic, or placebo, for glabellar lines. Day-30 responder rates were 87.2% for Jeuveau, 82.8% for Botox Cosmetic and 4.2% for placebo, an absolute difference of 4.4% with a 95% confidence interval of -1.9 to 10.8.
Juvederm Voluma XC in the cheeks: 85.6% of treated subjects met a one-grade improvement at 6 months, 85.2% at 12 months and 67.1% at 24 months. Juvederm Volbella XC in the lips: 80.3% at 3 months, down to 61.8% at 12 months.
That use is off-label in the US; the FDA labeling for Hylenex lists three indications and dissolving filler is not one of them. Juvederm gels were among the most enzyme-resistant in laboratory testing, needing 300 units to degrade within an hour.
Jeuveau's 2019 approval makes it newer than Botox Cosmetic (2002), Dysport (2009) and Xeomin's first cosmetic approval (2011). Newer is not the same as better, and in this case newer comes with a narrower approval: glabellar lines only.
There is one more piece of published data on Jeuveau worth knowing, and it is often reported wrongly. A post-hoc look at the men in the same Phase III programme - 25 in one arm, 31 in the other - found numerically higher responder percentages for prabotulinumtoxinA at every timepoint, but the difference was not statistically significant at any visit, and the prabotulinumtoxinA arm had a higher incidence of treatment-related headache and eyelid ptosis. That is an underpowered subgroup analysis from the sponsor's own trial. It does not show Jeuveau outperformed Botox Cosmetic in men.
The broader pattern across toxin head-to-head trials is consistent: at manufacturer-recommended doses, the repeated finding in the glabella is no clinically meaningful difference between brands. What genuinely differs is the unit scale, onset and price.
These signs can mean filler has entered a blood vessel. Time matters in hours.
Sudden vision change, blurring or loss of vision in either eye
Pain that is severe or out of proportion to the procedure
Skin that turns white or pale soon after the injection, then goes dusky, grey, purple or mottled
Any stroke-like symptom: weakness, drooping, slurred speech, confusion
Vision loss from filler is usually permanent: In a review of 511 published cases going back to 1906, of the 318 reporting a visual outcome, 6.0% recovered completely and 68.2% did not recover at all; hyaluronic acid was the material in 79.6% of the recent cases. Pain is not a reliable warning - it was mild or absent in 47% of intravascular events in a survey of experienced injectors.
Swelling that keeps growing after the first few days
A lump that will not settle
Redness spreading outward from the site, or a fever
Tenderness or firmness appearing weeks or months later
Filler that appears to have moved
A drooping eyelid or brow after the toxin